Gastrointestinal AE with cagrisema were more than with semagutide or cagrilintide monotherapy, however the SAE and AE leading to medication discontinuation were minimal and similar between the groups [87, 90] A programme of phase 3 clinical trials (REDEFINE) assessing the safety and efficacy of cagrisema in people with obesity (NCT05567796, NCT05394519, NCT05813925) is currently ongoing
Special populations may require modified dosing approaches for Semaglutide / Cyanocobalamin Injection
Journal of Aerosol Medicine and Pulmonary Drug Delivery 32 (3), A22 (2019)
The Japanese say 500umol/L is their ideal range, with 400umol/L being the lowest they want to see and yet we Australians are saying 150umol/L is ok
Cagrilintide activates amylin receptors, producing satiety and gastric slowing through distinct pathways
PE-22-28 does not Mood effects : PE-22-28 has demonstrated antidepressant effects